Collegium Pharmaceutical, Inc. (COLL) AI Stock Analysis

Collegium Pharmaceutical, Inc. is a specialized pharmaceutical company dedicated to advancing medications tailored for effective pain management. At the core of its product portfolio is Xtampza ER, an abuse-deterrent formulation of extended-release oxycodone designed to provide consistent pain relief while deterring misuse. In addition, the company offers Nucynta ER and Nucynta IR, which are tapentadol formulations catering to extended-release and immediate-release pain management needs. Founded in 2002 and based in Stoughton, Massachusetts, the company focuses on developing and commercializing advanced pain therapies that address chronic pain while prioritizing patient safety through abuse-deterrent formulations.

Revenue expanded at a 5-year CAGR of 20.3% from FY2020 through FY2025, rising from $276.9M in FY2021 to $780.6M in FY2025. Annual net income reached $62.9M in FY2025, following $69.2M in FY2024 and $48.2M in FY2023, while gross margin remained steady at 59.3%. Over the trailing twelve months, revenue totaled $808.2M with an operating margin of 5.7% and a profit margin of 5.9%. For the latest quarter ended June 30, 2026, quarterly revenue grew 6.3% year-over-year, while quarterly earnings declined 46.6%.

As of June 30, 2026, Collegium Pharmaceutical held $129.5M in cash and short-term investments against $857.8M in total debt, resulting in net debt of $728.3M. Total assets stood at $2.14B against shareholders' equity of $311.9M, producing a debt-to-equity ratio of 2.75 and a current ratio of 1.03. Cash generation remained strong in FY2025, with operating cash flow of $329.3M and free cash flow of $327.6M. Capital allocation in FY2025 included $1.7M in capital expenditures and $25.1M deployed into share buybacks, contributing to a 5-year share count change of -4.9%.

At a last close of $23.19, Collegium Pharmaceutical trades at a market capitalization of $755.0M and an enterprise value of $1.70B. Its trailing P/E of 18.3x and forward P/E of 3.4x sit below the median of its US-listed Healthcare peers (24.6x trailing and 17.3x forward). The stock's price-to-sales of 0.9x and EV-to-EBITDA of 4.4x are also below peer medians of 4.1x and 12.0x, respectively. Over the past year, the stock fell 30.2%, while the S&P 500 (SPY) gained 16.8%.

Wall Street coverage includes 5 Strong Buy, 2 Buy, and 1 Hold ratings, with no Sell or Strong Sell recommendations. The mean price target is $49.00, representing an upside of 111.3% over the last close of $23.19. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $833.1M and EPS of $7.46. Collegium Pharmaceutical beat EPS estimates in 3 of the last 4 quarters, and its next earnings release is scheduled for November 5, 2026.

This page is an AI-written research summary of Collegium Pharmaceutical, Inc. (COLL). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: COLL income statement, COLL balance sheet, COLL key metrics, COLL analyst forecast, COLL chart. See the COLL stock overview for the latest quote and news.